Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 1997

View Archived Issues

New agent for breast cancer in development at Zenyaku Kogyo

Oxygen carrier tested in patients with sickle cell disease

AmBisome approved in Russia

Fujisawa Foundation gives research grants

HemoCleanse submits 510(k) for ThermoChem-HT

R&D partnership announced between Helix BioPharma and PENCE

DiagnoCure granted U.S. patent for nanoerythrosomes

Patent for dry powder inhaler issued to TheraTech

CytoGam approved for marketing in Canada

Texas Biotechnology and SmithKline Beecham form marketing alliance for Novastan

IL-1ra tested for corneal transplant

YH-439 metabolites identified in rat urine

Labopharm: Q1 1997 highlights

Pain management: How to take control

DaunoXome approved in Russia

Genzyme Transgenics' cancer vaccine elicits immune response in myeloma patients

Results of RPR Gencell's gene therapy for Parkinson's disease reported

AVE seeks FDA approval for stent products

New analgesic/antiinflammatory compounds from Korea

First launch for new angiotensin II blocker

NMDA antagonist enters phase I for epilepsy

Atypical beta-adrenoceptor agonists from Glaxo Wellcome

Transkaryotic Therapies allowed European patent for gene therapy technology

Algos and NIDA enter into collaboration for heroin addiction treatment

Seragen grants U.S. Surgical option to restenosis product

Shionogi's beta-lactam antibiotic launched in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...